Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation

CDK4/6 plays a crucial role in various cancers and is an effective anticancer drug target. However, the gap between clinical requirements and approved CDK4/6 drugs is unresolved. Thus, there is an urgent need to develop selective and oral CDK4/6 inhibitors, particularly for monotherapy. Here, we stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yanting, Li, Xiandeng, Luo, Peifang, Chen, Huiting, Zhou, Yan, Zheng, Xueting, Yin, Yuan, Wei, Haoche, Liu, Hongji, Xia, Wen, Shi, Mingsong, Li, Xiaoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206264/
https://www.ncbi.nlm.nih.gov/pubmed/37234717
http://dx.doi.org/10.3389/fphar.2023.1154654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206264/
https://www.ncbi.nlm.nih.gov/pubmed/37234717
http://dx.doi.org/10.3389/fphar.2023.1154654

Ejemplares similares